We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.19%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$522M
AUM Growth
-$148M
Cap. Flow
-$183M
Cap. Flow %
-35.1%
Top 10 Hldgs %
68.85%
Holding
172
New
42
Increased
30
Reduced
27
Closed
64

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.7M
2
AZN icon
AstraZeneca
AZN
+$11.5M
3
XWEL icon
XWELL
XWEL
+$3.81M
4
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$3.63M
5
CVM icon
CEL-SCI Corp
CVM
+$2.66M

Top Sells

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$4.87M
2
IMMU
Immunomedics Inc
IMMU
+$4.25M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.12M
4
SPI
SPI Energy Co., Ltd. Ordinary Shares
SPI
+$3.57M
5
RMTI icon
Rockwell Medical
RMTI
+$3.04M

Sector Composition

Rank Sector Weight
1 Healthcare 17.64%
2 Industrials 0.71%
3 Technology 0.22%
4 Consumer Discretionary 0.14%
5 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLV icon
151
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
– –
-834
Closed -$8.8M
XLV icon
152
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
– –
-4,000
Closed -$422K
XLV icon
153
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.2B
– –
-4,634
Closed -$48.9M
QCLS
154
Q/C Technologies Inc
QCLS
$22.3M
– –
-50
Closed -$675K
PAVMZ
155
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
– –
-436,973
Closed -$364K
CNTG
156
DELISTED
Centogene N.V. Common Shares
CNTG
– –
-182,275
Closed -$1.72M
NXTP
157
DELISTED
NextPlay Technologies, Inc. Common Stock
NXTP
– –
-6,729
Closed -$297K
FRTX
158
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-16,042
Closed -$652K
MDGSW
159
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
– –
-544,940
Closed -$93K
BLU
160
DELISTED
BELLUS Health Inc.
BLU
– –
-880,400
Closed -$2M
NVCN
161
DELISTED
Neovasc Inc.
NVCN
– –
-40,376
Closed -$2.16M
SRNE
162
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-606,298
Closed -$4.87M
BXRX
163
PUT
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
– –
0
– -$114K
ODT
164
PUT
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-354
Closed -$475K
TRIL
165
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-1,860
Closed -$2.64M
IMMU
166
DELISTED
Immunomedics Inc
IMMU
– –
-50,000
Closed -$4.25M
ZOM
167
DELISTED
Zomedica Corp.
ZOM
– –
-470,548
Closed -$52K
GNCA
168
CALL
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-1,032
Closed -$236K
GNCA
169
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-312,666
Closed -$716K
SPI
170
DELISTED
SPI Energy Co., Ltd. Ordinary Shares
SPI
– –
-425,762
Closed -$3.57M
TEUM
171
PUT
DELISTED
Pareteum Corporation
TEUM
– –
-299
Closed -$20K
3 4 5 6
7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sabby Management held 172 positions worth $522M, down 22% from $670M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $183M in Q4 2020, closing 64 positions and reducing 27 holdings. Its most notable exit was Sorrento Therapeutics, Inc., an estimated $4.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 12% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in REVIVA PHARMA HLDGS INC worth $3.13M.

  • Sabby Management's largest Q4 2020 buy was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M.
  • Sabby Management added most to Biogen in Q4 2020, an estimated $18.7M increase.
  • Sabby Management's biggest Q4 2020 reduction was Rockwell Medical, cutting an estimated $3.04M.
  • Sabby Management fully exited Sorrento Therapeutics, Inc. in Q4 2020, selling an estimated $4.87M.
  • Sabby Management's ten largest holdings make up 69% of its $522M portfolio in Q4 2020.
  • Sabby Management opened 42 new positions and closed 64 in Q4 2020.
  • Sabby Management's portfolio value fell 22% quarter-over-quarter to $522M.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.